NasdaqGS - Nasdaq Real Time Price USD

Regeneron Pharmaceuticals, Inc. (REGN)

973.80 +5.80 (+0.60%)
At close: May 10 at 4:00 PM EDT
973.00 -0.80 (-0.08%)
After hours: May 10 at 6:27 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Leonard S. Schleifer M.D., Ph.D. Co-Founder, President, CEO & Co-Chairman 8.18M -- 1953
Dr. George D. Yancopoulos M.D., Ph.D. Co-Founder, President, Chief Scientific Officer & Co-Chairman 7.76M -- 1960
Dr. Andrew J. Murphy Ph.D. Executive Vice President of Research 1.68M 21.37M 1959
Mr. Daniel P. Van Plew Executive VP and GM of Industrial Operations & Product Supply 2.01M 10.67M 1973
Mr. Christopher R. Fenimore CPA Senior VP of Finance & CFO -- -- 1971
Ms. Patrice Gilooly Senior Vice President of Quality Assurance & Operations -- -- --
Mr. Bob McCowan Senior VP of IT & Chief Information Officer -- -- --
Mr. Ryan Crowe Senior Vice President of Investor Relations & Strategic Analysis -- -- --
Mr. Joseph J. LaRosa Executive VP, General Counsel & Secretary 1.75M 23.23M 1959
Ms. Melissa Lozner Senior VP & Chief Compliance Officer -- -- --

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000 https://www.regeneron.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
13,677

Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Corporate Governance

Regeneron Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 10; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Aug 01, 2024 - Aug 05, 2024
Regeneron Pharmaceuticals, Inc. Earnings Call

Related Tickers

VRTX Vertex Pharmaceuticals Incorporated
422.78
+0.90%
 
CRSP CRISPR Therapeutics AG
51.17
-4.44%
 
MDGL Madrigal Pharmaceuticals, Inc.
205.25
-0.81%
 
NTLA Intellia Therapeutics, Inc.
24.46
-1.61%
 
SRPT Sarepta Therapeutics, Inc.
131.82
-0.36%
 
ALNY Alnylam Pharmaceuticals, Inc.
150.47
-0.59%
 
BNTX BioNTech SE
91.67
-0.42%
 
BMRN BioMarin Pharmaceutical Inc.
81.03
-0.84%
 
MRNA Moderna, Inc.
117.31
-4.39%
 
VKTX Viking Therapeutics, Inc.
73.64
-8.18%